
Those following along with AbCellera Biologics Inc. (NASDAQ:ABCL) will no doubt be intrigued by the recent purchase of shares by Carl Hansen, CEO, President & Chairperson of the company, who spent a stonking US$699k on stock at an average price of US$11.54. There's no denying a buy of that magnitude suggests conviction in a brighter future, although we do note that proportionally it only increased their holding by 0.1%.
Notably, that recent purchase by Carl Hansen is the biggest insider purchase of AbCellera Biologics shares that we've seen in the last year. That means that an insider was happy to buy shares at above the current price of US$11.49. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.
AbCellera Biologics insiders may have bought shares in the last year, but they didn't sell any. The average buy price was around US$6.38. It is certainly positive to see that insiders have invested their own money in the company. However, we do note that they were buying at significantly lower prices than today's share price. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
Check out our latest analysis for AbCellera Biologics
AbCellera Biologics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.
For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. AbCellera Biologics insiders own about US$815m worth of shares (which is 22% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
It's certainly positive to see the recent insider purchases. We also take confidence from the longer term picture of insider transactions. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Once you factor in the high insider ownership, it certainly seems like insiders are positive about AbCellera Biologics. One for the watchlist, at least! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing AbCellera Biologics. Be aware that AbCellera Biologics is showing 3 warning signs in our investment analysis, and 1 of those shouldn't be ignored...
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.